News for Mind Medicine (MindMed) Inc. (MMDWF)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

MindMed (MNMD) to report Q2 2025 financial results on July 31, 2025. The live webcast will be available at 4:30 p.m. EDT. The webcast replay will be

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates

MindMed appoints Brandi L. Roberts as Chief Financial Officer, starting June 2, 2025. Roberts brings over 25 years of financial leadership experience in

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) was one of the stocks that was covered in that article. Wall Street analysts believe MNMD has a 285% upside potential over the next 12 months. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company dedicated […]

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) was one of the stocks that was covered in that article.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NMNMD.OQ - Mind Medicine (MindMed) IncQ1 2025 Mind Medicine (MindMed) Inc Earnings CallMay 08,

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates

Mind Medicine (Nasdaq: MNMD) to announce its Q1 2025 financial results on May 8, 2025. A live webcast of the earnings report will be available at 8:00 a

MindMed (MNMD) has commenced dosing in its Phase 3 Emerge study for Major Depressive Disorder (MDD). The study will assess the efficacy

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NMNMD.OQ - Mind Medicine (MindMed) IncQ4 2024 Mind Medicine (MindMed) Inc Earnings CallMar 06,

The following slide deck was published by Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsStephanie Fagan - Chief Corporate...

–First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data…

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand